The Big Boots Standing Tallest in 2025 Q4 Earnings: BOOT, PLTR, and CAH Lead the Way

The 2025 fourth quarter earnings season wrapped up with a resounding success, culminating with major technology companies sharing blockbuster results. Throughout this period, three standout performers emerged wearing the biggest boots in their respective sectors—Boot Barn, Palantir, and Cardinal Health. Each of these companies not only exceeded market expectations but also positioned themselves as clear leaders for investor consideration heading into 2026.

Boot Barn Marches Forward with Strong Retail Performance

Boot Barn commands attention as one of the session’s biggest boots in retail expansion and operational excellence. The company’s performance metrics tell a compelling story: revenue growth accelerated 16% year-over-year, while same-store sales climbed an impressive 5.7%. This dual growth pattern signals that Boot Barn is succeeding on both fronts—its established locations are performing well, and the company continues opening new doors to capture market share.

The expansion narrative continues with 25 new store locations added during the quarter, pushing the total store count to 514 locations by period’s end. For a retail-focused enterprise, this growth momentum matters significantly to investors seeking big boots operations with proven execution capabilities.

Profitability improvements further strengthen the case. Gross margins expanded to 39.9% compared to 39.3% in the year-ago period, marking another quarter of positive momentum after rebounding from 2023 lows. Retail investors particularly watch margin progression closely, as it directly translates to bottom-line strength. Boot Barn’s margin trajectory remains favorable, contributing to its strong post-earnings momentum and forward guidance.

Adding to the bullish outlook, the company carries a Zacks Rank #1 (Strong Buy) designation, reflecting analyst confidence in the earnings path ahead for fiscal 2026. The investment community clearly believes Boot Barn’s big boots strategy is resonating with customers and delivering sustainable returns.

Palantir Demonstrates Unstoppable Growth Momentum

Palantir’s performance throughout the period showcased exceptional operational execution across its business lines. Total revenue reached $1.4 billion, representing a striking 70% year-over-year surge—a figure that underscores the company’s commanding market position in data analytics and AI-driven solutions.

The United States segment served as the growth engine, generating $1.1 billion in revenue and climbing 93% year-over-year. Even more impressive is the sequential growth rate of 28%, demonstrating acceleration on a quarter-by-quarter basis. This performance reveals a company firing on multiple cylinders simultaneously.

Contract wins also paint an optimistic picture. Palantir closed over $4.2 billion in total contract value throughout the period, a gain exceeding 130% compared to the year-ago quarter. The expanding customer base reflects growing market acceptance, with customer counts surging 34% year-over-year. These metrics collectively illustrate a company successfully translating platform innovation into market traction.

The fiscal year 2026 earnings per share outlook remains decidedly bullish based on analyst projections. While recent stock price action has been mixed, the underlying business fundamentals and forward guidance support long-term investor confidence. Palantir carries a Zacks Rank #2 (Buy) rating, positioning it as an attractive holding for growth-oriented portfolios.

Cardinal Health Delivers Dual Beats and Raises Outlook

Cardinal Health surprised investors with a double beat relative to consensus expectations, defying a year marked by revenue stagnation through most of 2024. Sales expanded 18.8% year-over-year, while adjusted earnings per share grew an impressive 36.3%—a profitability surge that clearly caught analyst attention.

The company’s resurgence gained momentum through broad-based strength across operating segments. Pharmaceuticals and Specialty Solutions—representing roughly 90% of total revenue—led the charge with 19% year-over-year sales growth. This segment-level performance validates the strength underlying the consolidated results.

Management’s confidence in the turnaround proved evident through upward guidance revisions. Cardinal Health now expects adjusted EPS in the $10.15 to $10.35 range for fiscal 2026, with the midpoint implying 24.5% year-over-year growth. This guidance update has sparked positive estimate revisions among the analyst community, further validating the company’s positive momentum.

Cardinal Health similarly holds a Zacks Rank #2 (Buy) designation, reflecting constructive sentiment toward the company’s trajectory through the next fiscal year and beyond.

Why These Three Companies Matter for Investors in 2026

The convergence of strong operational results, favorable forward guidance, and solid analyst support positions Boot Barn, Palantir, and Cardinal Health as meaningful holdings for portfolio construction. Each company demonstrated the ability to not only meet current quarter expectations but also provide investors with reasonable confidence regarding near-term earnings power. Boot Barn’s expansion strategy, Palantir’s market traction, and Cardinal Health’s profitability turnaround collectively represent the kind of big boots corporate performance that tends to support equity returns over time.